SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending amid anticipation for its upcoming event, with community members discussing potential product announcements and their impact, particularly around AI and live translation features. Some traders anticipate a "sell the news" event, while others remain bullish, expecting a continued rise. The broader conversation includes discussions about Apple's innovation, potential market impact, and comparisons to competitors like DUOL.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Fueled by a newly announced infrastructure deal with Microsoft, Nebius Group N.V. is trending as the community discusses the potential impact of this contract on the company's future growth and valuation. Bullish sentiment is strong, with many believing the stock is significantly undervalued and predicting further upside as the AI sector gains momentum. Some are closely watching for analyst upgrades and institutional investment following the news.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as investors analyze its potential within the AI sector, with community members weighing positive partnerships against concerns about financial reporting. Discussions revolve around the company's ability to capitalize on data center spending and partnerships. Some traders express frustration with the stock's price action, while others remain optimistic about long-term growth.

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos Inc 

CaliberCos ($CWD) is trending due to discussions around a recent volatile trading session, with community members debating the merits of holding versus selling. The stock's earlier surge, reportedly fueled by the company's initial purchase of Chainlink tokens, has given way to concerns about dilution and insider selling, sparking a battle between bulls and bears. Some traders are pointing to other stocks as potential plays, drawing comparisons to previous high-momentum tickers.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

QMMM is experiencing significant volatility, driven by discussions around its potential as a pump-and-dump scheme and comparisons to other high-flying stocks. The community is actively debating its merits as a short versus long opportunity, with some eyeing a possible squeeze and others expressing skepticism about its long-term value. News about the company entering the crypto sector with a substantial treasury plan may also be contributing to the stock's increased attention.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to increased attention surrounding its AI technology and potential for growth in the retail sector, with community members highlighting the company's patented technology and recent partnerships. Online chatter suggests many are optimistic about Rezolve's prospects, particularly its potential to integrate AI solutions into retail businesses, while others discuss possible entry points and future dilution concerns. The stock's recent price movement and high trading volume are also contributing to the ongoing buzz.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$OPT Opthea terminates COAST trial, announces ShORe trial misses endpoint 
 
Opthea announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its second Phase 3 trial ShORe in patients with wet AMD. Following the negative results of the COAST Phase 3 trial announced on March 24, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other stakeholders was to accelerate the ShORe trial topline data readout, including in consultation with its Development Funding Agreement investors.  
 
The global ShORe Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 0.5 mg ranibizumab every four weeks, as per label, versus 0.5 mg ranibizumab monotherapy. The trial did not meet its primary endpoint of mean change in best corrected visual acuity from baseline to week 52. In wet AMD patients with minimally classic and occult lesions, participants receiving sozinibercept combination therapy with a dosing regimen of every four weeks or every eight weeks achieved a mean change in BCVA of 13.3 or 12.9 letters from baseline to week 52, respectively, versus 14.2 letters with ranibizumab monotherapy.  
 
In the overall population, participants receiving sozinibercept combination therapy with a dosing regimen of every four weeks or every eight weeks achieved a mean change in BCVA of 13.3 and 12.6 letters from baseline to week 52, respectively, versus 14.3 letters with ranibizumab monotherapy. Sozinibercept combination therapy was well tolerated. Following the negative results of the COAST and ShORe trials, Opthea and the DFA Investors agreed to discontinue the development of sozinibercept in wet AMD with immediate effect, and that this decision did not constitute a termination event under the DFA resulting in any amount payable by Opthea.  
 
It remains possible that under the DFA, in certain circumstances upon or following termination of the DFA, Opthea could become required to pay a multiple of the amount funded by the DFA Investors that would have a material adverse impact on the solvency of the company. As previously disclosed, termination can be triggered by a range of events, including, among other things, Opthea&#39;s insolvency, in which case Opthea will be obligated to pay a multiple of the amounts funded by the DFA Investors.  
 
Opthea continues active discussions with the DFA Investors, pursuant to and as required under the DFA, to explore possible options to deliver the best outcome for the Company and its shareholders. Opthea estimates it will have unaudited cash and cash equivalents of $100M at the end of March.

StockTwits Web

Opthea Limited - ADR

 Opthea terminates COAST trial, announces ShORe trial misses endpoint 
 
Opthea announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its second Phase 3 trial ShORe in patients with wet AMD. Following the negative results of the COAST Phase 3 trial announced on March 24, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other stakeholders was to accelerate the ShORe trial topline data readout, including in consultation with its Development Funding Agreement investors.  
 
The global ShORe Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 0.5 mg ranibizumab every four weeks, as per label, versus 0.5 mg ranibizumab monotherapy. The trial did not meet its primary endpoint of mean change in best corrected visual acuity from baseline to week 52. In wet AMD patients with minimally classic and occult lesions, participants receiving sozinibercept combination therapy with a dosing regimen of every four weeks or every eight weeks achieved a mean change in BCVA of 13.3 or 12.9 letters from baseline to week 52, respectively, versus 14.2 letters with ranibizumab monotherapy.  
 
In the overall population, participants receiving sozinibercept combination therapy with a dosing regimen of every four weeks or every eight weeks achieved a mean change in BCVA of 13.3 and 12.6 letters from baseline to week 52, respectively, versus 14.3 letters with ranibizumab monotherapy. Sozinibercept combination therapy was well tolerated. Following the negative results of the COAST and ShORe trials, Opthea and the DFA Investors agreed to discontinue the development of sozinibercept in wet AMD with immediate effect, and that this decision did not constitute a termination event under the DFA resulting in any amount payable by Opthea.  
 
It remains possible that under the DFA, in certain circumstances upon or following termination of the DFA, Opthea could become required to pay a multiple of the amount funded by the DFA Investors that would have a material adverse impact on the solvency of the company. As previously disclosed, termination can be triggered by a range of events, including, among other things, Opthea's insolvency, in which case Opthea will be obligated to pay a multiple of the amounts funded by the DFA Investors.  
 
Opthea continues active discussions with the DFA Investors, pursuant to and as required under the DFA, to explore possible options to deliver the best outcome for the Company and its shareholders. Opthea estimates it will have unaudited cash and cash equivalents of $100M at the end of March.

DonCorleone77

@DonCorleone77 GLMD is a coiled spring. Shorts are trapped under cash and book value with zero debt. The chart’s tightening, supply’s vanishing, and every dip is getting scooped. Major catalysts are around the corner tied to GLP-1 obesity + fibrosis this has all the signs of a high-voltage squeeze. When volume hits, this won&#39;t walk it’ll fly.  ...

 GLMD is a coiled spring. Shorts are trapped under cash and book value with zero debt. The chart’s tightening, supply’s vanishing, and every dip is getting scooped. Major catalysts are around the corner tied to GLP-1 obesity + fibrosis this has all the signs of a high-voltage squeeze. When volume hits, this won't walk it’ll fly.  ...